Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy

Publication Date: November 29, 2018

Key Points

Key Points

Women with node-positive breast cancer should receive extended therapy including an aromatase inhibitor (AI) for up to a total of 10 years of adjuvant endocrine treatment.

Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.

The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.

A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.

Treatment

...eatment

...mendations on Extended Therapy...

...women with node-negative breast cancer are potent...

...node-positive breast cancer should be offered ex...

...receiving extended adjuvant endocrine therapy sho...

...s prevention of secondary or contralateral brea...

...xtended therapy carries ongoing risks and s...


...mmendations on Ovarian Suppress...

...commends that higher risk patients should re...

...ge II or Stage III breast cancers who w...

...Stage I or II breast cancers at higher risk of...

...with Stage I breast cancers not warran...

...n with node-negative cancers 1 centimeter or le...

...n suppression may be administered with eith...


Table 1. Recommended Pharmaceuticals...


...gnostic Factors for Recurrence After 5 Years of...